211 related articles for article (PubMed ID: 19475481)
1. Prevalence and type distribution of human papillomavirus in 5,000 British Columbia women--implications for vaccination.
Moore RA; Ogilvie G; Fornika D; Moravan V; Brisson M; Amirabbasi-Beik M; Kollar A; Burgess T; Hsu R; Towers L; Lo J; Matisic J; Brooks-Wilson A
Cancer Causes Control; 2009 Oct; 20(8):1387-96. PubMed ID: 19475481
[TBL] [Abstract][Full Text] [Related]
2. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.
Muñoz N; Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Brown DR; Koutsky LA; Tay EH; Garcia PJ; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Steben M; Bosch FX; Dillner J; Huh WK; Joura EA; Kurman RJ; Majewski S; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan JT; Lupinacci LC; Giacoletti KE; Sings HL; James MK; Hesley TM; Barr E; Haupt RM
J Natl Cancer Inst; 2010 Mar; 102(5):325-39. PubMed ID: 20139221
[TBL] [Abstract][Full Text] [Related]
3. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of
Lehtinen M; Lagheden C; Luostarinen T; Eriksson T; Apter D; Harjula K; Kuortti M; Natunen K; Palmroth J; Petäjä T; Pukkala E; Siitari-Mattila M; Struyf F; Nieminen P; Paavonen J; Dubin G; Dillner J
BMJ Open; 2017 Aug; 7(8):e015867. PubMed ID: 28821519
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of High risk Human Papillomavirus in cervical dysplasia and cancer samples from twin cities in Pakistan.
Gul S; Murad S; Javed A
Int J Infect Dis; 2015 May; 34():14-9. PubMed ID: 25725135
[TBL] [Abstract][Full Text] [Related]
5. Prevalence and genotyping of high risk human papillomavirus in cervical cancer samples from Punjab, Pakistan.
Siddiqa A; Zainab M; Qadri I; Bhatti MF; Parish JL
Viruses; 2014 Jul; 6(7):2762-77. PubMed ID: 25036463
[TBL] [Abstract][Full Text] [Related]
6. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
[TBL] [Abstract][Full Text] [Related]
7. Human papilloma virus prevalence, genotype distribution, and pattern of infection in Thai women.
Suthipintawong C; Siriaunkgul S; Tungsinmunkong K; Pientong C; Ekalaksananan T; Karalak A; Kleebkaow P; Vinyuvat S; Triratanachat S; Khunamornpong S; Chongsuwanich T
Asian Pac J Cancer Prev; 2011; 12(4):853-6. PubMed ID: 21790214
[TBL] [Abstract][Full Text] [Related]
8. Baseline prevalence and type distribution of human papillomavirus in healthy Chinese women aged 18-25 years enrolled in a clinical trial.
Zhao FH; Zhu FC; Chen W; Li J; Hu YM; Hong Y; Zhang YJ; Pan QJ; Zhu JH; Zhang X; Chen Y; Tang H; Zhang H; Durand C; Datta SK; Struyf F; Bi D;
Int J Cancer; 2014 Dec; 135(11):2604-11. PubMed ID: 24740547
[TBL] [Abstract][Full Text] [Related]
9. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.
Lehtinen M; Paavonen J; Wheeler CM; Jaisamrarn U; Garland SM; Castellsagué X; Skinner SR; Apter D; Naud P; Salmerón J; Chow SN; Kitchener H; Teixeira JC; Hedrick J; Limson G; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; De Carvalho NS; Germar MJ; Peters K; Mindel A; De Sutter P; Bosch FX; David MP; Descamps D; Struyf F; Dubin G;
Lancet Oncol; 2012 Jan; 13(1):89-99. PubMed ID: 22075171
[TBL] [Abstract][Full Text] [Related]
10. Prevalence and type distribution of human papillomavirus in healthy Japanese women aged 20 to 25 years old enrolled in a clinical study.
Konno R; Tamura S; Dobbelaere K; Yoshikawa H
Cancer Sci; 2011 Apr; 102(4):877-82. PubMed ID: 21251162
[TBL] [Abstract][Full Text] [Related]
11. Distribution of human papillomavirus genotypes in cervical intraepithelial neoplasia and invasive cervical cancer in Canada.
Coutlée F; Ratnam S; Ramanakumar AV; Insinga RR; Bentley J; Escott N; Ghatage P; Koushik A; Ferenczy A; Franco EL
J Med Virol; 2011 Jun; 83(6):1034-41. PubMed ID: 21503917
[TBL] [Abstract][Full Text] [Related]
12. A population-based study of human papillomavirus genotype prevalence in the United States: baseline measures prior to mass human papillomavirus vaccination.
Wheeler CM; Hunt WC; Cuzick J; Langsfeld E; Pearse A; Montoya GD; Robertson M; Shearman CA; Castle PE;
Int J Cancer; 2013 Jan; 132(1):198-207. PubMed ID: 22532127
[TBL] [Abstract][Full Text] [Related]
13. High frequency of HPV genotypes 59, 66, 52, 51, 39 and 56 in women from Western Mexico.
Molina-Pineda A; López-Cardona MG; Limón-Toledo LP; Cantón-Romero JC; Martínez-Silva MG; Ramos-Sánchez HV; Flores-Miramontes MG; de la Mata-González P; Jave-Suárez LF; Aguilar-Lemarroy A
BMC Infect Dis; 2020 Nov; 20(1):889. PubMed ID: 33238902
[TBL] [Abstract][Full Text] [Related]
14. Declining rates of cervical intraepithelial neoplasia in British Columbia, Canada: An ecological analysis on the effects of the school-based human papillomavirus vaccination program.
Donken R; van Niekerk D; Hamm J; Spinelli JJ; Smith L; Sadarangani M; Albert A; Money D; Dobson S; Miller D; Lee M; Mitchell-Foster S; Krajden M; Naus M; Ogilvie G
Int J Cancer; 2021 Jul; 149(1):191-199. PubMed ID: 33586169
[TBL] [Abstract][Full Text] [Related]
15. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
[TBL] [Abstract][Full Text] [Related]
16. Rationale and design of a multicenter prospective cohort study for the eVALuation and monitoring of HPV infections and relATEd cervical diseases in high-risk women (VALHIDATE study).
Orlando G; Tanzi E; Chatenoud L; Gramegna M; Rizzardini G;
BMC Cancer; 2012 May; 12():204. PubMed ID: 22646512
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of HPV 16/18 vaccines on sexually active 18-23 year old women and the impact of HPV vaccination on organized cervical cancer screening.
Sigurdsson K; Sigvaldason H; Gudmundsdottir T; Sigurdsson R; Briem H
Acta Obstet Gynecol Scand; 2009; 88(1):27-35. PubMed ID: 19031282
[TBL] [Abstract][Full Text] [Related]
18. Assessment of the effectiveness of HPV16/18 infection referred for colposcopy in cervical cancer screening in Northwest of China.
Zhang Q; Zhao M; Cao D; Wei X; Wang L; Li Y; Yang T; Zhao J; Pei M; Jia H; Cao S; Quan S; Yang X
J Med Virol; 2018 Jan; 90(1):165-171. PubMed ID: 28710863
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of human papillomavirus types in high-grade cervical intraepithelial neoplasia and cancer in Italy.
Carozzi FM; Tornesello ML; Burroni E; Loquercio G; Carillo G; Angeloni C; Scalisi A; Macis R; Chini F; Buonaguro FM; Giorgi Rossi P;
Cancer Epidemiol Biomarkers Prev; 2010 Sep; 19(9):2389-400. PubMed ID: 20826836
[TBL] [Abstract][Full Text] [Related]
20. Type-specific HPV prevalence in invasive cervical cancer in the UK prior to national HPV immunisation programme: baseline for monitoring the effects of immunisation.
Mesher D; Cuschieri K; Hibbitts S; Jamison J; Sargent A; Pollock KG; Powell N; Wilson R; McCall F; Fiander A; Soldan K
J Clin Pathol; 2015 Feb; 68(2):135-40. PubMed ID: 25410654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]